Literature DB >> 10679806

Fibrinogen Longmont: a dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method.

J B Lefkowitz1, T DeBoom, A Weller, S Clarke, D Lavrinets.   

Abstract

A new fibrinogen variant was discovered as a result of discrepancies found in routine laboratory screening. The patient, a healthy 37-year-old woman, had a mild bleeding history. Initial coagulation studies on the patient revealed a prolonged prothrombin time (PT) and a normal activated partial thromboplastin time (APTT). Further investigation on the patient and her mother demonstrated both had a PT with no end point using an optical detection method (ACL3000+) and a normal PT using an electromechanical detection method (ST4 Clot Detection System). The APTT for both the patient and her mother were essentially normal with both optical and mechanical detection methods. The patient and her mother also had markedly prolonged thrombin time and reptilase time results on the ACL3000+, but they were normal on the ST4. Coagulation test results on the patient's father were all normal. We believe the fibrinogen defect in this family may affect fibrin polymerization only enough to effect light scatter interpretation, while there is enough polymerization to increase plasma viscosity and yield an end point using an electromechanical analyzer. This report should alert pathologists and clinicians to possible discrepancies between mechanical and spectrophotometric clot testing methods. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679806     DOI: 10.1002/(sici)1096-8652(200003)63:3<149::aid-ajh8>3.0.co;2-#

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Optical and mechanical clot detection methodologies: a comparison study for routine coagulation testing.

Authors:  Nilgun Tekkesin; Cumhur Kılınc
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

2.  Identification of novel mutations in patients with fibrinogen disorders and genotype/phenotype correlations.

Authors:  Elena Chinni; Giovanni Tiscia; Giovanni Favuzzi; Filomena Cappucci; Giuseppe Malcangi; Rossana Bagna; Claudia Izzi; Domenica Rizzi; Valerio De Stefano; Elvira Grandone
Journal:  Blood Transfus       Date:  2018-10-08       Impact factor: 3.443

3.  Combined use of Clauss and prothrombin time-derived methods for determining fibrinogen concentrations: Screening for congenital dysfibrinogenemia.

Authors:  Liqun Xiang; Meiling Luo; Jie Yan; Lin Liao; Weijie Zhou; Xuelian Deng; Donghong Deng; Peng Cheng; Faquan Lin
Journal:  J Clin Lab Anal       Date:  2017-09-18       Impact factor: 2.352

4.  Use of chromogenic assay of factor X to accept or reject INR results in Warfarin treated patients.

Authors:  Michael J Sanfelippo; Wendy Zinsmaster; Doris L Scherr; Gene R Shaw
Journal:  Clin Med Res       Date:  2009-07-22

5.  Fibrinogen Longmont: A Clinically Heterogeneous Dysfibrinogenemia with Discrepant Fibrinogen Results Influenced by Clot Detection Method and Reagent.

Authors:  Becky Leung; Joanne Beggs; Jane Mason
Journal:  TH Open       Date:  2022-01-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.